Nocturne Acquisition Postpones Cognos Therapeutics Vote

Nocturne Acquisition announced that doay's shareholder meeting to vote on a business combination has been pushed back to March 19 at 9 a.m. Eastern. The redemption deadline has been extended to two days before the rescheduled meeting.

No reason was given for the delay.

The SPAC initially called a Jan. 30 meeting for shareholders to vote on the proposed merger with Cognos Therapeutics, but that vote was pushed to Feb. 6, then delayed again so Nocturne could continue to solicit proxies.

Cognos specializes in drug delivery devices for brain and spinal cancers, neurodegenerative disorders (such as Alzheimer's and Parkinson's disease), epilepsy, and stroke.

Nocturne raised $100 million in a March 2021 with plans at that time to focus on targets bringing to market disruptive technologies in the / and artificial intelligence technology sectors. Redemptions in the nearly three years since have reduced the trust to about $20 million as of Dec. 29. Read more.


Source: Nocturne Acquisition Postpones Cognos Therapeutics Vote